CC BY 4.0 · Thromb Haemost 2019; 119(10): 1665-1674
DOI: 10.1055/s-0039-1693694
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

ABT-737 Triggers Caspase-Dependent Inhibition of Platelet Procoagulant Extracellular Vesicle Release during Apoptosis and Secondary Necrosis In Vitro

Hao Wei
1   Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
,
Matthew T. Harper
1   Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
› Author Affiliations
Funding None.
Further Information

Publication History

16 February 2019

12 June 2019

Publication Date:
07 September 2019 (online)

Abstract

Platelet lifespan is limited by activation of intrinsic apoptosis. Apoptotic platelets are rapidly cleared from the circulation in vivo. ABT-737 triggers platelet apoptosis and is a useful tool for studying this process. However, in vitro experiments lack clearance mechanisms for apoptotic platelets. To determine whether apoptotic platelets progress to secondary necrosis, apoptosis was triggered in human platelets with ABT-737, a BH3 mimetic. Platelet annexin V (AnV) binding, release of AnV+ extracellular vesicles (EVs), and loss of plasma membrane integrity were monitored by flow cytometry. ABT-737 triggered AnV binding, indicating phosphatidylserine exposure, release of AnV+ EVs, and a slow loss of plasma membrane integrity. The latter suggests that apoptotic platelets progress to secondary necrosis in vitro. These responses were dependent on caspase activation and Ca2+ entry. Surprisingly, although intracellular Ca2+ concentration increased, AnV+ EV release was not dependent on the Ca2+-dependent protease, calpain. On the contrary, ABT-737 downregulated the ability of the Ca2+ ionophore, A23187, to trigger calpain-dependent release of AnV+ EVs. This was dependent on caspase activity as, when caspases were inhibited, ABT-737 increased the ability of A23187 to trigger AnV+ EV release. These data suggest that apoptotic platelets progress to secondary necrosis unless they are cleared. This may affect the interpretation of ABT-737-triggered signaling in platelets in vitro. Ca2+-dependent AnV+ EV release is downregulated during apoptosis in a caspase-dependent manner, which may limit the potential consequences of secondary necrotic platelets.

Note

The data are available from the corresponding author on reasonable request.


Authors' Contributions

H.W. performed experiments, analyzed data, and edited the manuscript. M.T.H. designed experiments, wrote, and edited the manuscript


Supplementary Material

 
  • References

  • 1 Lebois M, Josefsson EC. Regulation of platelet lifespan by apoptosis. Platelets 2016; 27 (06) 497-504
  • 2 Kile BT. The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014; 165 (02) 217-226
  • 3 Mason KD, Carpinelli MR, Fletcher JI. , et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128 (06) 1173-1186
  • 4 Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015; 22 (07) 1071-1080
  • 5 Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic?. Cell Death Differ 2018; 25 (01) 56-64
  • 6 Schoenwaelder SM, Jarman KE, Gardiner EE. , et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118 (06) 1663-1674
  • 7 Vogler M, Hamali HA, Sun XM. , et al. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117 (26) 7145-7154
  • 8 Souers AJ, Leverson JD, Boghaert ER. , et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19 (02) 202-208
  • 9 Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 2018; 34 (06) 879-891
  • 10 Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: a new wave in hematooncology. Exp Hematol 2018; 61: 10-25
  • 11 Kumari S, Chaurasia SN, Kumar K, Dash D. Anti-apoptotic role of sonic hedgehog on blood platelets. Thromb Res 2014; 134 (06) 1311-1315
  • 12 Zhang S, Ye J, Zhang Y. , et al. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. J Thromb Haemost 2013; 11 (01) 149-160
  • 13 Winkler J, Rand ML, Schmugge M, Speer O. Omi/HtrA2 and XIAP are components of platelet apoptosis signalling. Thromb Haemost 2013; 109 (03) 532-539
  • 14 Chatterjee M, Borst O, Walker B. , et al. Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res 2014; 115 (11) 939-949
  • 15 Rukoyatkina N, Mindukshev I, Walter U, Gambaryan S. Dual role of the p38 MAPK/cPLA2 pathway in the regulation of platelet apoptosis induced by ABT-737 and strong platelet agonists. Cell Death Dis 2013; 4: e931
  • 16 Harper MT, Londoño JEC, Quick K. , et al. Transient receptor potential channels function as a coincidence signal detector mediating phosphatidylserine exposure. Sci Signal 2013; 6 (281) ra50
  • 17 Harper MT, Poole AW. Bcl-xL-inhibitory BH3 mimetic ABT-737 depletes platelet calcium stores. Blood 2012; 119 (18) 4337-4338
  • 18 Sachet M, Liang YY, Oehler R. The immune response to secondary necrotic cells. Apoptosis 2017; 22 (10) 1189-1204
  • 19 Wei H, Malcor JM, Harper MT. Lipid rafts are essential for release of phosphatidylserine-exposing extracellular vesicles from platelets. Sci Rep 2018; 8 (01) 9987
  • 20 van Kruchten R, Mattheij NJ, Saunders C. , et al. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood 2013; 121 (10) 1850-1857
  • 21 Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15 (02) 135-147
  • 22 Yano Y, Shiba E, Kambayashi J. , et al. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb Res 1993; 71 (05) 385-396
  • 23 Fox JEB, Austin CD, Reynolds CC, Steffen PK. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. J Biol Chem 1991; 266 (20) 13289-13295
  • 24 Mattheij NJA, Braun A, van Kruchten R. , et al. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. FASEB J 2016; 30 (02) 727-737
  • 25 Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468 (7325): 834-838
  • 26 Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science 2013; 341 (6144): 403-406
  • 27 Hampton MB, Vanags DM, Pörn-Ares MI, Orrenius S. Involvement of extracellular calcium in phosphatidylserine exposure during apoptosis. FEBS Lett 1996; 399 (03) 277-282
  • 28 Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006; 20 (01) 1-15
  • 29 Liu X, Van Vleet T, Schnellmann RG. The role of calpain in oncotic cell death. Annu Rev Pharmacol Toxicol 2004; 44: 349-370
  • 30 Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31 (01) 15-26
  • 31 Choo H-J, Kholmukhamedov A, Zhou C, Jobe S. Inner mitochondrial membrane disruption links apoptotic and agonist-initiated phosphatidylserine externalization in platelets. Arterioscler Thromb Vasc Biol 2017; 37 (08) 1503-1512
  • 32 Tait SW, Green DR. Mitochondrial regulation of cell death. Cold Spring Harb Perspect Biol 2013; 5 (09) a008706
  • 33 Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer DD. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell 2009; 20 (23) 4871-4884
  • 34 Kushnareva Y, Newmeyer DD. Bioenergetics and cell death. Ann N Y Acad Sci 2010; 1201: 50-57
  • 35 Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 2010; 207 (09) 1807-1817
  • 36 Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10 (12) 826-837
  • 37 Krysko DV, Agostinis P, Krysko O. , et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 2011; 32 (04) 157-164
  • 38 Chen Q, Vogel S, Loughran P, Zuckerbraun BS, Billiar T, Neal MD. Platelet derived HMGB1 regulates thrombosis and organ injury following trauma. Shock 2015; 43 (06) 24
  • 39 Vogel S, Bodenstein R, Chen Q. , et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125 (12) 4638-4654
  • 40 Wang Y, Fang C, Gao H. , et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest 2014; 124 (05) 2160-2171
  • 41 Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett 2010; 584 (22) 4491-4499
  • 42 Mahajan A, Herrmann M, Muñoz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol 2016; 7: 35